Cross-Border Cooperation for Medicines, Vaccines, Procurement, and Health Workforce in South Africa

Download the Full Paper
Health Financing2026

Exemplar Overview

This exemplar examines South Africa's role as a regional industrial and regulatory anchor for medicines and vaccines in Southern Africa, detailing its cross-border support and pooled procurement contributions.

South Africa is the center of the pharmaceutical supply chain in sub-Saharan Africa, supplying an estimated 60% of regional pharmaceuticals. Its vaccine manufacturing base consists of Aspen Pharmacare, the Biovac Institute, and Afrigen Biologics. Biovac secured a R1.47 billion investment package in 2026 to build Africa's first end-to-end multi-vaccine manufacturing site. Nationally, the 2024 National Health Insurance (NHI) Act aims to establish a single purchaser model, while regionally South Africa acts as an anchor for the SADC Pooled Procurement Services and cross-border health security.

Biopharmaceutical Scale-Up Review
Cross-Border Supply Chain Mapping
Regulatory Harmonization Audit
Pooled Procurement Assessment

Policy Recommendations

  • Blended finance (public equity and private debt) combined with off-take guarantees is the template for scalable vaccine manufacturing in Africa.

  • Regional pooled procurement depends on a strong domestic price reference to negotiate costs down (achieving up to 40% reductions).

  • Cross-border health security requires synchronized vaccination campaigns and shared surveillance architectures.

  • National health policy changes (like NHI) propagate across borders, affecting regional workforce migration and medical tourism patterns.

Key Numbers

60%

Of pharmaceuticals in sub-Saharan Africa supplied by South Africa

1.47B

Rand investment package secured by Biovac in 2026

40%

Average drug price reduction achieved through SADC pooled procurement

450M

Vaccine doses delivered by Biovac cumulatively across Southern Africa

Country Context

South Africa

Southern Africa
RECs: SADC
Income Level: UMIC
View Country Profile

Key Findings

  • South Africa supplies approximately 60% of the pharmaceuticals consumed in sub-Saharan Africa.

  • The Biovac Institute secured R1.47 billion in April 2026 to build Africa’s first end-to-end multi-vaccine facility.

  • Zambia, Mozambique, Malawi, and Zimbabwe operate under the SADC Pooled Procurement Services (SPPS) using South African reference pricing.

  • The National Institute for Communicable Diseases (NICD) in Johannesburg coordinates SADC-wide laboratory and outbreak surveillance.